JenniferAnnWoyachMD

Oncology • Columbus, OH

Hematologic Oncology

Professor

Join to view full profile

Dr. Woyach is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Woyach's full profile

Already have an account?

Office
455d Wiseman Hall
Columbus, OH 43210
Phone+1 614-293-3196

Fax+1 614-293-4812

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
Ohio State University HospitalResidency, Internal Medicine, 2005 - 2008
Ohio State University College of MedicineClass of 2005

Certifications & Licensure

OH State Medical License 2005 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) Start of enrollment: 2010 Oct 01
Completed
Phase 1
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Start of enrollment: 2014 Jan 17
Active, not recruiting
Phase 2
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2018 Aug 16
Active, not recruiting
Phase 1
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2019 Jan 31
Active, not recruiting
Phase 3
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Start of enrollment: 2019 Nov 05
Completed
Phase 1
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Start of enrollment: 2020 Oct 23
Completed
Phase 1
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2021 Mar 18
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

Predictive ability of the Cancer and Aging Research Group chemotherapy toxicity calculator in hematologic malignancy.
Ashley E Rosko, Ying Huang, Sarah A Wall, Alice Mims, Jennifer Woyach
Journal of Geriatric Oncology. 2025-01-01
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
Haematologica. 2025-01-01
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia.
Janani Ravikrishnan, Daisy Y Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai
Haematologica. 2025-01-01

Journal Articles

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
Jennifer Woyach, MD, Cancer Discovery
Ibrutinib and Aspergillus: A Btk-Targeted Risk
Jennifer Woyach, MD, Blood

Abstracts/Posters

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (C...
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

MRD Testing to Guide Treatment Decisions in CLL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Response Comes of Age in Chronic Lymphocytic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up.
2019 ASCO Annual Meeting - 6/1/2019
Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic LeukemiaMarch 2020

Press Mentions

Meet the OSU Cancer Center Doctor Who Calls His CLL Leukemia a 'Silver Lining'August 28th, 2024
Ohio State University Studying Effects of COVID-19 Shot in Cancer PatientsJanuary 18th, 2022
100 Columbus Doctors: Please Require Masks for All Kids This Upcoming School YearJuly 27th, 2021
Join now to see all